| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3854853 | Journal of Renal Nutrition | 2016 | 9 Pages |
Abstract
The current evidence for treatment with MA in patients receiving dialysis is sparse with few high-quality trials. The safety of using MA beyond 24Â weeks is unknown, and use of MA is associated with significant AEs. At this time, oral MA should be used with significant caution, and only when other treatment options are unavailable.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Lori D. BSc (Pharm), PharmD, Stewart Nadurak, Cali BSc (Pharm), CDE, Lori BA (Hons), MLIS, Navdeep MD, PhD, FRCPC,